1. Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma
   Michael Müller et al, 2021, Cancers CrossRef
2. Introducing HDAC-Targeting Radiopharmaceuticals for Glioblastoma Imaging and Therapy
   Liesbeth Everix et al, 2023, Pharmaceuticals CrossRef
3. Programmed cell death, redox imbalance, and cancer therapeutics.
   Xiaofeng Dai et al, 2021, Apoptosis CrossRef
4. Cellular senescence in glioma
   Rafał Chojak et al, 2023, J Neurooncol CrossRef
5. Combination Drug Therapy of Glioblastoma: Lessons from 3D In Vitro Models and the Roadmap for Future Research
   Mahsa Vaezzadeh et al, 2023, Advanced Therapeutics CrossRef
6. Metabolic Roles of HIF1, c-Myc, and p53 in Glioma Cells
   Cristina Trejo-Solís et al, 2024, Metabolites CrossRef
7. TIM-3/CD68 double-high expression in Glioma: Prognostic characteristics and potential therapeutic approaches
   Wanming Hu et al, 2024, International Immunopharmacology CrossRef
8. In Vitro Assessment of the Role of p53 on Chemotherapy Treatments in Neuroblastoma Cell Lines.
   Idoia Blanco-Luquin et al, 2021, Pharmaceuticals (Basel) CrossRef
9. Inhibition of histone deacetylase 6 by tubastatin A as an experimental therapeutic strategy against glioblastoma
   Alejandro Urdiciain et al, 2021, Glioma CrossRef
10. 3-Deazaneplanocin A (DZNep): A Drug That Deserves a Second Look
    Victor E. Marquez, 2024, J. Med. Chem. CrossRef
11. The Role of HDAC6 in Glioblastoma Multiforme: A New Avenue to Therapeutic Interventions?
    Francesco Spallotta et al, 2024, Biomedicines CrossRef
12. Epigenetic dysregulation in glioblastoma: potential pathways to precision medicine
    Vijeta Prakash et al, 2024, Neurogenetics CrossRef